Home > Inhibitors & Agonists > Ras-Raf-MAPK-ERK > Raf
Cat. No. Product name CAS No.
DC12376 AZ304 Featured

AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively.

942507-42-8
DC10994 Balamapimod

Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential..

863029-99-6
DC12278 Belvarafenib

Belvarafenib is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.

1446113-23-0
DC7718 B-Raf IN 1 Featured

B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM).

950736-05-7
DC8921 B-Raf inhibitor 1 Featured

B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respectively.

1093100-40-3
DC7008 BRAF inhibitor Featured

BRAF inhibitor is a potent BRAF inhibitor.

918505-61-0
DC10005 CCT196969 Featured

CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity.

1163719-56-9
DC8777 CEP-32496 hydrochloride

CEP-32496 Hcl is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

1227678-26-3
DC8196 CEP-32496 Featured

CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

1188910-76-0
DC5149 Dabrafenib Featured

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Phase 3.

1195765-45-7
DC4103 Dabrafenib Mesylate Featured

Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity.

1195768-06-9
DC3102 GDC-0879 Featured

GDC-0879 is a novel potent, selective B-Raf inhibitor for B-RafV600E with IC50 of 0.13 nM.

905281-76-7
DC8810 GW-5074 Featured

GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

220904-83-6
DC8362 L-779,450 Featured

L-779,450 is a potent, ATP-competitive Raf (Raf kinase) inhibitor (IC50 = 10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively.

303727-31-3
DC7018 LGX-818(Encorafenib) Featured

LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

1269440-17-6
DC10099 BGB283

Lifirafenib(BGB-283) is a Novel potent and selective RAF Kinase and EGFR inhibitor.

1446090-77-2
DC10828 LXH254 Featured

LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor.

1800398-38-2
DC8344 LY3009120 Featured

LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity.

1454682-72-4
DC8727 PF-04880594

PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively.

1111636-35-1
DC1071 Vemurafenib (PLX4032)

PLX4032 (Vemurafenib, RG7204, Zelboraf, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM.

918504-65-1
DC6301 PLX-4720 Featured

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

918505-84-7
DC9814 PLX7904(PB04) Featured

PLX7904(PB04) is a potent and selective paradox-breaker RAF inhibitor.

1393465-84-3
Page 1 / Total 2 FirstPrevNextLastGoto